Reports Q1 revenue $13.7B, consensus $14.09B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Financial Outlook: Hold Rating Amidst Short-Term Challenges and Long-Term Potential
- Notable companies reporting before tomorrow’s open
- Pfizer call volume above normal and directionally bullish
- Eli Lilly, Pfizer, Amgen – Trump’s 25% Pharma Tariffs Could Drain $51B Annually
- ‘Regulatory Headwinds Set to Bite,’ Says Top Analyst on Novavax Stock (NVAX)